Article

NLRP13 mutation as a predictive indicator for immune checkpoint inhibitor efficacy in melanoma and NSCLC

2025-07-31

Abstract excerpt

<title>Abstract</title> <p>Background Robustly predictive indicators could assist in maximizing immune checkpoint inhibitor (ICI) treatment responses. A key point in immunotherapies is to select tumor patients who will respond to immune checkpoint inhibitor (ICI). Effective indicators could accurately evaluate the ICI treatment efficacy. NLRP proteins have been revealed to implicate in inflammatory processes via...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ccbb39a2-2b06-5a90-83af-daa848bb39eb
DOI: 10.21203/rs.3.rs-7155327/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

NLRP13 mutation as a predictive indicator for immune checkpoint inhibitor efficacy in melanoma and NSCLCDOI 10.21203/rs.3.rs-7155327/v1Read

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma.Semantic proximity Read

Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancerSemantic proximity Read

The Role of NLRP3 in The Prognosis and Immune Infiltrates of Skin Cutaneous Melanoma (SKCM)Semantic proximity Read

NLRP3 is a Novel Prognostic Biomarker and Correlates With Immune Infiltrates in Lung Adenocarcinoma and Skin Cutaneous MelanomaSemantic proximity Read

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.Semantic proximity Read

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity Read

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerSemantic proximity Read

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.Semantic proximity Read

Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor respondersSemantic proximity Read

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.Semantic proximity Read

Tumor <i>NLRP3</i> Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I ExpressionSemantic proximity Read

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.Semantic proximity Read